AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01204892 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
Study NCT01204892 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration
Description: 20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
Study NCT01407861 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training
Description: Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
Study NCT01407861 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic endurance Training
Description: Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
Study NCT00399152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine Oral Dose
Study NCT00399152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Sunitinib oral dose
Study NCT00870779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid
Description: 20mg/kg 3 hours prior to surgery
Study NCT02131298 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib Alone
Description: A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection
Study NCT02131298 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib plus itraconazole
Description: Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
Study NCT06531447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Every 21 days 6 cycles
Study NCT06531447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Every 21 days (First and 8th days) 6 cycles
Study NCT06531447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Every 21 days 4 cycles
Study NCT06531447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Every 21 days 4 cycles
Study NCT06531447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Every 21 days 4 cycles or once a week for 12 weeks
Study NCT00920192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foretinib
Description: Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,
Study NCT02516059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone/naloxone
Description: Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
Study NCT02516059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
Study NCT02516059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
Study NCT02516059 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Study NCT02516059 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: epidural catheter
Study NCT00766415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: Oral tablet, twice daily, 4 weeks treatment
Study NCT00766415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02755935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Nucleus CI532
Description: cochlear implantation
Study NCT04479891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib tablet
Description: single oral dose of SHR6390 or co-administered with itraconazole
Study NCT04479891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole capsule
Description: 200 mg itraconazole QD
Study NCT02041182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Visit Questionnaire
Study NCT02041182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Visit Questionnaire
Study NCT02825394 — intervention group
Intervention type: OTHER
Intervention: anti-Xa activity point-of-care testing (aXa-POCT)
Study NCT04468568 — intervention group
Intervention type: DRUG
Intervention: Atosiban
Description: Atosiban intravenous. Dose: attack of 6.75 mg, and maintenance of 300 mcg / min for 3 hours, and 100 mcg / min for 21 hours.
Study NCT03172390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4D Cardiac Magnetic Resonance
Description: 4D Cardiac Magnetic Resonance for patients with a ascending aorta dilatation without current indication for surgery for measured parameters of ascending aorta
Study NCT02825394 — intervention group
Intervention type: OTHER
Intervention: ecarin clotting time point-of-care testing (ECT-POCT)
Study NCT03347227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Wide area circumferential catheter ablation for pulmonary vein isolation of persistent atrial fibrillation
Study NCT04592692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated Liposome (PEGLip)
Description: Intravenous co-administration of PEGLip with Simoctocog alfa
Study NCT04592692 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PEGylated Liposome (PEGLip)
Description: Intravenous co-administration of PEGLip with Simoctocog alfa
Study NCT03347227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Wide area circumferential catheter ablation for pulmonary vein isolation of persistent atrial fibrillation
Study NCT01898195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline will be provided for three months.
Study NCT01898195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline will be provided for three months.
Study NCT01898195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Text messages will be developed twice daily for three months
Study NCT00764816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: grain (soy) protein diet
Description: The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
Study NCT00764816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: casein (meat) protein diet
Description: The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
Study NCT01898195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Behavioral Therapy
Description: Seven Adherence Behavioral Therapy sessions will given over a three month period
Study NCT03457259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC and/or PICCline
Description: Pt. will receive PVC and/or PICCline
Study NCT03457259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Midline
Description: Pt. will receive midline
Study NCT02278276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium polysulthionate
Description: Bioavailable composition of α-sulfur
Study NCT02278276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg capsules containing placebo
Study NCT00389935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 50 - 200 mg once at nightime
Study NCT04468568 — intervention group
Intervention type: DRUG
Intervention: Terbutaline
Description: Terbutaline intravenous. Dose: 2.5 mg in 500 mL saline, infusion rate of 30 mL / hr (150 mcg / h) during the surgery and for 24 hours.
Study NCT04306731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nanotechnology Structured water Magnalife
Description: Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules
Study NCT04306731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim
Description: Antibiotic
Study NCT04306731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ordinary bottled drinking water
Description: Placebo
Study NCT02897778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entinostat
Description: Single, supratherapeutic dose of entinostat given orally.
Study NCT01528046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine (VCR) = 1.5 mg/m\^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
Study NCT01528046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan (IRN) = 50 mg/m\^2/day, days 1-5, IV over 60 minutes
Study NCT01528046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TEM) = 50 mg/m\^2/day by mouth (PO) Days 1-5
Study NCT01528046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.
Study NCT02147262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline orally, 100 mg, bid, 14 days
Study NCT02147262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline orally, 100 mg, bid, 28 days
Study NCT00984828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velcade
Description: velcade 1.3mg/m2 D1, 4, 8 and 11
Study NCT00984828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: velcade
Description: velcade 1.3mg/m2 D1, 4, 8 and 11
Study NCT03287102 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Macular hole surgery
Description: Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade
Study NCT00552682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg, QD
Description: Duloxetine 60 mg, 1 table/day, 1 year
Study NCT03794999 — intervention group
Intervention type: DRUG
Intervention: Benralizumab-exposure
Description: Exposure is defined as any dose of benralizumab for any length of time from 8 weeks prior to Last Mentrual Period (LMP) through the end of pregnancy, as reported by the mother and validated through medical record review. The 8-week cut-off prior to LMP is based upon the terminal half-life of benralizumab of approximately 15 days (clearance of benralizumab is based on five half-lives).
Study NCT03794999 — intervention group
Intervention type: DRUG
Intervention: Exposure to other asthma medications
Description: Exposure to asthma medications for any number of days, at any dose, and at any time from LMP up to the date of enrollment, but no exposure to benralizumab during pregnancy or within 8 weeks prior to LMP.
Study NCT03596879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCBTI
Description: Online access to the digital CBTI program Sleepio based off of traditional face-to-face Cognitive Behavioral Therapy, six weekly sessions done online.
Study NCT03596879 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education
Description: Six weekly email messages with sleep hygiene recommendations. Subjects are encouraged to read through the information and apply it to their sleep.
Study NCT05189145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate
Description: 8mg orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle then assess by ultrasound
Study NCT05189145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate
Description: 8mg orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle then assess by ultrasound
Study NCT05189145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hormonal monitoring progesterone, estradiol, luteinizing hormone
Description: Serum Progesterone, estrogen \& LH measured on day 13 after priming endometrium with 8mg estradiol valerate on a daily basis beginning as early as the first day of menstrual cycle.
Study NCT05189145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal ultrasound examination
Description: Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation
Study NCT05189145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: transvaginal ultrasound examination
Description: Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation
Study NCT05189145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 400 Mg Vaginal Suppository
Description: Progesterone supplements given in form of daily two vaginal prontogest suppositories400 mg each
Study NCT05189145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 400 Mg Vaginal Suppository
Description: Progesterone supplements given in form of daily two vaginal prontogest suppositories400 mg each
Study NCT05189145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hormonal monitoring progesterone and estradiol
Description: Measuring the serum Progesterone \& Estradiol in the early morning on the day of embryo transfer an progesterone supplementation adjusted as follows: Group II A: If P4 levels \< 5ng/dl, one 100 mg intramuscular injection daily added, Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added. Group II C: If P4 levels >10ng, continued on 400 mg prontogest suppositories twice daily
Study NCT05189145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: group II A: 100 mg intramuscular injection daily Group II B: If P4 levels 5-10ng/dl dydrogesterone added
Study NCT03216681 — intervention group
Intervention type: DRUG
Intervention: Hoat Huyet Nhat Nhat
Description: Administered orally twice a day, 2 tablets each time, for 45 days.
Study NCT03216681 — intervention group
Intervention type: DRUG
Intervention: Tanakan 40mg
Description: Administered orally three times a day, 1 tablet each time, for 45 days.
Study NCT02787785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Implantable Cardioverter Defibrillator
Description: The S-ICD is an entirely subcutaneous implantable cardioverter defibrillator.
Study NCT03537222 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Myeloma Patient Outcome Scale (MyPOS)
Description: Patients complete the MyPOS questionnaire on quality of life
Study NCT02091804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Group
Description: The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts.
Study NCT02091804 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-List group
Description: The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts.
Study NCT02973451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Guided Bupivacaine
Description: Bupivacaine Laparoscopic GuidedTransversus Abdominis Plane Block
Study NCT02973451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local Bupivacaine
Description: Bupivacaine Trocar Site Infiltration
Study NCT01839227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurologic and neuropsychologic tests
Description: Cognitive functioning was assessed with the following test: Korean Mini-Mental State Examination (K-MMSE) and visuomotor test of D-LOTCA battery.~Regional cerebral oxygen saturation was continuously monitored using the INVOS 5100 (somatics,Troy, MI) with bifrontal placement of two sensors before the induction of the anesthesia until the end of operation.~Baseline rSO2 was defined as the average saturation value over a 1 min period before induction of general anesthesia, beginning approximately 3 min after the sensors were applied in supine position. After the induction, baseline prone rSO2 was defined over a 5min period after the change of position.~There is no intervention were made according to rSO2 values. Physiologic variables including BIS, PaCO2,PaO2, glucose, electrolyte, hematocrit, HR, MAP, and nasopharyngeal temperature were measured every 1 hours during the surgery.
Study NCT03003728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26
Study NCT02932631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THERAPY CONTROL AND MOVEMENT OF INDUCTION
Description: Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb.
Study NCT02897778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo-matching entinostat (containing inactive ingredients matching the appearance of the active product).
Study NCT01144702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate & mefloquine combination
Description: A therapeutic trial of a single arm for prospective evaluation of responses of individuals with uncomplicated malaria by P. falciparum treated with combination artesunate + mefloquine for three days and monitored clinically and biochemically for 42 days.
Study NCT03003728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 200 mg/m2 Ivia intravenous infusion on day -3
Study NCT03003728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant (ASCT)
Description: ASCT on day -2
Study NCT03003728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Expanded Natural Killer (ENK) Cells
Description: ENK cell infusion on day 0
Study NCT03469700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: Induction of general anesthesia will be performed followed by endotracheal intubation. General anesthesia is induced with 0.5-1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.6 mg/kg/h rocuronium, 60% nitrous oxide and 40% oxygen with Ultiva (Remifentanyl) 0.1-0.2 μg/kg/hr
Study NCT03469700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: Induction of general anesthesia will be performed followed by endotracheal intubation. General anesthesia is induced with 0.5-1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.6 mg/kg/h rocuronium, 60% nitrous oxide and 40% oxygen with Ultiva (Remifentanyl) 0.1-0.2 μg/kg/hr